Articles published by LEO Pharma A/S

LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas

October 01, 2026

From LEO Pharma A/S

Via Business Wire

LEO Pharma continues global rollout of Anzupgo® (delgocitinib) cream with submission of New Drug Application in China

October 16, 2025

From LEO Pharma A/S

Via Business Wire

LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)

September 18, 2025

From LEO Pharma A/S

Via Business Wire

LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis

May 09, 2025

From LEO Pharma A/S

Via Business Wire

LEO Pharma Announces Publication of Head-to-Head DELTA FORCE Study Results in The Lancet

April 24, 2025

From LEO Pharma A/S

Via Business Wire

LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 2025

March 08, 2025

From LEO Pharma A/S

Via Business Wire

LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data in Adults with Moderate-to-Severe Atopic Dermatitis at the 2024 AAD Annual Meeting

March 08, 2024

From LEO Pharma A/S

Via Business Wire

LEO Pharma Presents Data at 2024 Winter Clinical and Maui Derm Conferences

January 12, 2024

From LEO Pharma A/S

Via Business Wire

LEO Pharma Presents Adbry® (tralokinumab-ldrm) Data at 2023 Fall Clinical Dermatology Conference

October 20, 2023

From LEO Pharma A/S

Via Business Wire

LEO Pharma Receives Positive CHMP Opinion for New Adtralza® (tralokinumab) Injection Device

June 23, 2023

From LEO Pharma A/S

Via Business Wire

Japan Ministry of Health, Labor and Welfare Approves Manufacturing and Marketing of Adtralza® (tralokinumab) in Japan for Adults with Atopic Dermatitis

December 23, 2022

From LEO Pharma A/S

Via Business Wire

LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents

October 20, 2022

From LEO Pharma A/S

Via Business Wire

LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis

September 16, 2022

From LEO Pharma A/S

Via Business Wire

LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress

August 25, 2022

From LEO Pharma A/S

Via Business Wire

LEO Pharma Presents New Interim Long-Term Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 RAD Conference

April 11, 2022

From LEO Pharma A/S

Via Business Wire

LEO Pharma Presents New Interim Long-Term Safety and Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 AAD Annual Meeting

March 25, 2022

From LEO Pharma A/S

Via Business Wire

LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United States

February 17, 2022

From LEO Pharma A/S

Via Business Wire

Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis

October 22, 2021

From LEO Pharma A/S

Via Business Wire

LEO Pharma announces European Commission approval of Adtralza® (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis

June 22, 2021

From LEO Pharma A/S

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.